Neuphoria Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
-$4.07next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly14.2MTarget: Sufficient to fund operations through the second fiscal quarter of 2027
Merck Partnership Milestone Payments Annually15MTarget: Up to $450 million in potential biobucks
Watch Items
- Strategic Alternatives Review and Potential AcquisitionTrigger: Receipt of definitive acquisition agreement or merger proposal (e.g., revised offers from Lynx1 Master Fund LP)Action: Board evaluation of proposals in consultation with financial advisor H.C. Wainwright & Co. to maximize shareholder value.
- BNC210 Development in Post-Traumatic Stress Disorder (PTSD)Trigger: Initiation of Phase 2b (SYMPHONY) dose-ranging trialAction: Assess clinical trial design, lower-dose safety/efficacy, and capital requirements before advancing to Phase 3.
- Merck-led Phase 2 Trial of MK-1167 in Alzheimer's DiseaseTrigger: Topline data readout or clinical progress updates from MerckAction: Monitor partner execution and evaluate potential milestone payment triggers.
Research as of 20 Jun 2026